Literature DB >> 18079714

Lung-directed gene therapy in mice using the nonviral Sleeping Beauty transposon system.

Lalitha R Belur1, Kelly Podetz-Pedersen, Joel Frandsen, R Scott McIvor.   

Abstract

The Sleeping Beauty (SB) transposon is an integrative nonviral plasmid system. Here, we describe a protocol for SB-mediated transgene delivery using DNA/polyethyleneimine (PEI) complexes for long-term expression in mouse lungs. This protocol can be used for delivery of any plasmid-based vector system to mouse lungs, although long-term transgene expression will be obtained only when using the SB transposon or other integrating vector systems. The stages of this protocol are preparation of DNA-PEI complexes and injection of the complexes into the lateral tail vein of mice. We also provide protocols for assessing transgene expression using in vivo bioluminescence imaging and enzymatic assay of lung homogenates. The procedure can be completed within 24 h, starting from preparation of DNA-PEI complexes to analysis of transient transgene expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079714     DOI: 10.1038/nprot.2007.460

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  16 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system.

Authors:  Teiko Sumiyoshi; Nathalia G Holt; Roger P Hollis; Shundi Ge; Paula M Cannon; Gay M Crooks; Donald B Kohn
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

3.  PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer.

Authors:  Sai K Saridey; Li Liu; Joseph E Doherty; Aparna Kaja; Daniel L Galvan; Bradley S Fletcher; Matthew H Wilson
Journal:  Mol Ther       Date:  2009-10-06       Impact factor: 11.454

Review 4.  Advances in cell and gene-based therapies for cystic fibrosis lung disease.

Authors:  Mayumi Oakland; Patrick L Sinn; Paul B McCray
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

5.  miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice.

Authors:  Jun Xiao; Xiao-Ming Meng; Xiao R Huang; Arthur Ck Chung; Yu-Lin Feng; David Sc Hui; Cheuk-Man Yu; Joseph Jy Sung; Hui Y Lan
Journal:  Mol Ther       Date:  2012-03-06       Impact factor: 11.454

6.  Synergetic Targeted Delivery of Sleeping-Beauty Transposon System to Mesenchymal Stem Cells Using LPD Nanoparticles Modified with a Phage-Displayed Targeting Peptide.

Authors:  Kun Ma; Dong-Dong Wang; Yiyang Lin; Jianglin Wang; Valery Petrenko; Chuanbin Mao
Journal:  Adv Funct Mater       Date:  2013-03-06       Impact factor: 18.808

7.  CRISPR/Cas9 engineering of albino cystinuria Type A mice.

Authors:  Thomas M Beckermann; Richard C Welch; Felisha M Williams; Douglas P Mortlock; Feng Sha; Talat A Ikizler; Lauren E Woodard; Matthew H Wilson
Journal:  Genesis       Date:  2020-02-20       Impact factor: 2.487

Review 8.  Gene transfer to the outflow tract.

Authors:  Yalong Dang; Ralitsa Loewen; Hardik A Parikh; Pritha Roy; Nils A Loewen
Journal:  Exp Eye Res       Date:  2016-04-27       Impact factor: 3.467

9.  Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota.

Authors:  Lu Zhang; Ying Huang; Yang Zhou; Timothy Buckley; Hua H Wang
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

10.  Luminescence-based in vivo monitoring of NF-κB activity through a gene delivery approach.

Authors:  Fernando G Osorio; Jorge de la Rosa; José Mp Freije
Journal:  Cell Commun Signal       Date:  2013-03-21       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.